Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Accumulated Expenses (2016 - 2025)

Avalo Therapeutics' Accumulated Expenses history spans 12 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 68.34% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 68.34%, while the annual FY2025 figure was $2.0 million, 68.34% down from the prior year.
  • Accumulated Expenses reached $2.0 million in Q4 2025 per AVTX's latest filing, up from $327000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.5 million in Q4 2021 to a low of $327000.0 in Q2 2025.
  • Average Accumulated Expenses over 5 years is $5.2 million, with a median of $2.0 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: surged 1997.4% in 2022, then plummeted 95.41% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $16.5 million in 2021, then dropped by 20.01% to $13.2 million in 2022, then plummeted by 68.43% to $4.2 million in 2023, then skyrocketed by 51.41% to $6.3 million in 2024, then plummeted by 68.34% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Accumulated Expenses are $2.0 million (Q4 2025), $327000.0 (Q3 2025), and $327000.0 (Q2 2025).